Guaifenesin
| Evidence Level: L3 | Predicted Indications: 5 |
Table of Contents
Guaifenesin: From Expectorant to Nasal Cavity Disease
One-Sentence Summary
Guaifenesin is a widely marketed oral expectorant used to loosen chest mucus. The TxGNN model predicts it may be effective for nasal cavity disease, with 1 small Phase 2 pilot trial and 2 older narrative reviews so far. That is early-stage evidence and does not yet show efficacy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Expectorant for mucus and chest congestion (the US label records provided contain no indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Guaifenesin is generally understood to thin and loosen airway mucus. That is a general pharmacological assumption and is not confirmed by DrugBank data.
Chronic rhinitis and sinusitis involve thick or retained nasal and sinus secretions, so a mucus-thinning drug could plausibly help. The pediatric chronic rhinitis pilot trial tests this idea directly.
The TxGNN score is a model output, not clinical evidence. The other four predicted indications (acute laryngopharyngitis, faucial diphtheria, cervical disc degenerative disorder, papillary conjunctivitis) have no trials or literature. The last three have no plausible mechanistic link and are likely knowledge-graph artifacts.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01364467 | Phase 2 | Completed | 30 | 14-day pilot of oral guaifenesin in children aged 7–18 with chronic rhinitis. It compares nasal symptoms (SN-5 survey) with nasal airway volume and secretion properties. No results were provided, so no efficacy conclusion is possible. |
The registry summary mentions 36 children, while the recorded enrollment is 30. The record also does not clearly confirm randomization, blinding or a control arm, so this is treated as exploratory evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9065342 | 1997 | Review / clinical management | American Journal of Rhinology | Experience with 22 adult cystic fibrosis patients with chronic sinusitis, 8 of whom had sinus surgery, with management recommendations. Guaifenesin is not the focus. |
| 12487405 | 2002 | Review / clinical management | Logopedics, Phoniatrics, Vocology | Treatment strategies for allergic voice users. It notes that decongestants containing guaifenesin may be useful, which is indirect support only. |
Relevance screening of both papers is still pending. Neither reports a controlled test of guaifenesin for nasal disease.
US Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| ANDA213420 | Mucus Relief | Extended-release tablet |
| M012 | Guaifenesin | Solution |
| ANDA207342 | Mucus Relief | Tablet |
| M012 | Tussin Mucus and Chest Congestion Sugar Free | Liquid |
| ANDA217780 | Guaifenesin 1200 mg | Tablet |
The records provided do not include approved indication text. There are 20 authorizations in total, and the table lists 5.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only direct evidence is one small, completed Phase 2 pilot trial with no reported results, plus two indirect narrative reviews. The safety and label data are also missing. Guaifenesin’s long marketed use gives it a familiar profile, but the nasal indication is still a research question.
To proceed, the following is needed:
- Results or publication from NCT01364467, and confirmation of its design (randomization, blinding, control arm)
- Package insert warnings and contraindications, which currently block safety screening
- Mechanism of action data from DrugBank
- Route compatibility assessment, since oral guaifenesin is the only formulation tested
- A controlled trial in chronic rhinitis or sinusitis, if the pilot results are encouraging
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.